UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 ORor 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported) May 14, 2025~~1934

Date of report (Date of earliest event reported): September 19, 2025

LEXARIA BIOSCIENCE CORP.

(Exact name of registrant as specified in its charter)

Nevada

000-39874

20-2000871

~~20-2000871~~

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

(State or other jurisdictionof incorporation)

(Commission File Number)

(IRS EmployerIdentification No.)

100 – 740 McCurdy Road, Kelowna, BC Canada		V1X 2P7
100 - 740 McCurdy Road, Kelowna, BC Canada	V1X 2P7
(Address of principal executive offices)	(Zip Code)	~~(Zip Code)~~

~~Registrant’s telephone number, including area code~~ (250) 765-6424

~~(Former~~Registrant’s ~~name~~telephone ~~or former address~~number, ifincluding ~~changed~~area ~~since~~code ~~last report.)~~

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

Warrants to Purchase Common Stock

LEXX

LEXXW

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.002 ~~Entry~~Termination ~~into~~of a Material Definitive Agreement.

Effective September 19, 2025, Lexaria Bioscience Corp. (the “Company”) ~~via~~terminated ~~its~~the ~~wholly~~Capital ~~owned~~on ~~subsidiary,~~Demand™ ~~Lexaria~~Sales ~~(AU)~~Agreement ~~Pty~~with ~~Ltd~~JonesTrading Institutional Services LLC (~~“Lexaria~~the AU“Agent”), ~~has~~as originally entered into aon ~~Change~~August ~~Order~~21, ~~with~~2024 an(the ~~effective~~full ~~date~~text ofhaving ~~May~~been ~~14,~~filed ~~2025,~~as Exhibit 1.1 to the ~~terms~~Company’s ofCurrent ~~its~~Report ~~Project~~on ~~Agreement~~Form ~~(the~~8-K ~~“PA”)~~filed ~~with~~August ~~Novotech~~22, ~~(Australia~~2024) ~~Pty~~and, ~~Limited~~as ~~(“Novotech”)~~amended by Amendment No. ~~The~~ ~~Change~~1 ~~Order~~on ~~contemplates~~February 5, 2025 (the ~~addition~~full oftext ahaving ~~5th~~been ~~study~~filed ~~arm,~~as ~~investigating~~Exhibit ~~DehydraTECH~~10.1 to the Company’s Current Report on Form 8-~~tirzepatide~~K ~~capsules~~filed inFebruary ~~its~~5, ~~Australian~~2025) ~~clinical~~collectively ~~study~~the “~~DehydraTECH~~Sales ~~Cannabidiol~~Agreement”. The ~~alone~~Sales Agreement provided that the Company may issue and insell, ~~combination~~from ~~with~~time ~~glucagon-like~~to ~~peptide~~time, 1up ~~agonists~~to $5,000,000 in ~~pre-~~aggregate ~~and~~principal ~~Type~~amount IIof ~~Diabetes”~~shares (the “~~GLP-1-H24-4~~Shares”)~~. Receipt~~ of the ~~human~~Company’s ~~research~~common ~~ethics~~stock ~~committee~~through ~~approval~~or ~~for~~to ~~this~~the ~~5th~~Agent, ~~study~~as ~~arm was announced in~~ the Company’s ~~press~~sales ~~release~~agent ofor ~~February~~principal. ~~24,~~As ~~2025~~at ~~and~~the ~~since~~date ~~then~~of ~~Lexaria~~termination, AUthe ~~has~~Company ~~been~~had ~~working~~sold ~~with~~an ~~Novotech~~aggregate to14,995 ~~approve~~Shares anunder ~~increased~~the ~~budget~~Sales toAgreement ~~facilitate~~for ~~this~~gross ~~study~~proceeds ~~arm~~of ~~within GLP-1-H24-4~~$38,236. 00.

The Change Order also contemplates increasing the number of subjects previously approved in the PA for the four study arms from 20 to 24 subjects, in addition to the recruitment of 24 subjects for the 5th study arm investigating DehydraTECH-tirzepatide capsules.2

~~The finalized approved budget associated with this Change Order has resulted in additional approximate costs of AU$1,900,000.~~SIGNATURES

~~The~~Pursuant ~~description~~to the requirements of the ~~Change~~Securities ~~Order~~Exchange ~~with~~Act ~~Novotech~~of is1934, ~~qualified~~the inregistrant ~~its~~has ~~entirety~~duly bycaused ~~the~~this ~~agreement~~report ~~that~~to ~~will~~ be ~~filed~~signed ason anits ~~exhibit~~behalf toby the ~~Company’s~~undersigned ~~quarterly~~hereunto ~~10-Q~~duly ~~Periodic Report~~authorized.

2Date: September 25, 2025

~~SIGNATURES~~LEXARIA BIOSCIENCE CORP. /s/ Richard Christopher Name: Richard Christopher Title: Chief Executive Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~3

LEXARIA BIOSCIENCE CORP. /s/ Richard Christopher Richard Christopher CEO, Principal Executive Officer Date: June 12, 2025

Filing Compare · Lexaria Bioscience Corp.